Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ortfolio will continue to drive total revenue growth; however, the rate of growth will reduce in the fourth quarter as we will not benefit from the one off adjustment to ADDERALL XR Medicaid rebates and high level of royalties experienced in the same period last year. The consolidation of Movetis will also mean that combined R&D and SG&A spend for 2010 is likely to grow at marginally above 10% year on year.

Shire has made significant progress in 2010. Growth across our core portfolio, particularly the accelerated growth of our HGT business, has enabled us to increase our expectations of earnings while also making targeted investments in our pipeline and international structure. We expect to see solid earnings growth in 2011, but at a rate that reflects the pull ahead into 2010 of some of HGT's growth potential.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, future product launches in the next 12 months include:

- VYVANSE/VENVANSE for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD") in adolescents in the US and children in Brazil; - INTUNIV as adjunctive treatment to long acting oral stimulants for the treatment of ADHD in children and adolescents in the US; - EQUASYM(R) for the treatment of ADHD in certain European Union ("EU") countries; - RESOLOR(R) in certain EU countries, for the symptomatic treatment of chronic constipation in women for whom laxatives fail to provide adequate relief; - LIALDA/MEZAVANT for the maintenance of remission of ulcerative colitis in the US and for the treatment of ulcerative colitis in certain countries; - VPRIV for the treatment of type 1 Gaucher disease in certain European and Latin American countries; and - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angioedema ("HAE") in the US and certain European and Latin American countries. PRODUCT AND PIPELINE DEVELOPMENTS Products PENTASA(R) - for the treatment of Ulcer
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... MILWAUKEE, Wis. (PRWEB) , ... July 29, 2015 ... ... facility identification solutions, today announced its GHS Label Guide . To align ... Harmonized System (GHS), this guide includes explanations of label components, an example of ...
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... , ... convenient, solution for performing gene silencing experiments and ... Silencer Validated , and Silencer ... tedious labwork--associated with siRNA design and testing. Applied Biosystems' , ...
... Performance of New MessageAmp II on High Density Oligonucleotide , ... New ArrayScript, an M-MLV RT , engineered to maximize ... as little as , 100 ng of input RNA ... , cRNA synthesis powered by , ...
... the success of many downstream applications, ... For this reason, if you are planning , ... consider the factors that affect the quality of your RNA. , ... Responses to Injury , ...
Cached Biology Technology:Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 2Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 3Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 4Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 5Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 6Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 7Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success 8Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Determinants of RNA Integrity and Purity 2Determinants of RNA Integrity and Purity 3Determinants of RNA Integrity and Purity 4Determinants of RNA Integrity and Purity 5Determinants of RNA Integrity and Purity 6Determinants of RNA Integrity and Purity 7
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... kingdom was overgrown by vines when she fell into a ... University of Wisconsin at Milwaukee received more than a million ... real vines are overtaking the American tropics. Data from eight ... "We are witnessing a fundamental structural change in the physical ...
... a human cell and a bacterial cell met at a ... numbers, much less genetic material. In more scientific terms, a ... to bacteria. Until now. Northwestern Medicine researchers have discovered ... bacterial genome in this case, Neisseria gonorrhoeae , ...
Cached Biology News:Why are vines overtaking the American tropics? 2Gonorrhea acquires a piece of human DNA 2